Abstract:Immune checkpoint blockade has revolutionized the treatment landscape in a multitude of advanced cancers.1 However, only a small subset (∼20%) of unselected patients derived durable clinical benefit (DCB).2, 3 As a consequence, substantial efforts have been made to improve immunotherapy outcome, including approaches to combine immunotherapy with other anticancer treatments4, 5 and identification of biomarkers that could enrich for potential responders.6-9 In patients with advanced nonsmall-cell lung cancer (NSCLC), a number of biomarkers that can predict clinical benefit from anti-PD-(L)1 monotherapies have been identified,2, 6, 8, 10-16 including high tumor mutational burden (TMB), which reflects the overall neoantigen load.13 However, most current studies are based on tissue samples, which can be inadequate for multiple testing in patients with advanced disease. Liquid biopsy utilizing circulating tumor DNA (ctDNA) provides an alternative and minimally invasive source for molecular testing in the absence of tissue samples. Plasma-based next-generation sequencing (NGS) testing has demonstrated its potential for complementing tissue testing in the identification of actionable mutations and resistance mechanisms. In contrast to tissue samples, plasma has its unique advantages in long-term disease monitoring and overcoming tumor heterogeneity. Although blood TMB (bTMB) is a promising and clinically accessible biomarker, few studies exist evaluating its predictive value.17-20 Furthermore, TMB alone is insufficient to completely enrich for potential responders, and therefore, additional predictive biomarkers and new approaches that optimize response prediction are urgently needed. Previously, our group demonstrated that tissue TMB (tTMB) estimated by a 422-cancer-gene panel (GeneseeqPrime) in NSCLC patients is associated with clinical benefit from anti-PD-(L)1 therapies.15 In the current study, we performed targeted NGS of plasma ctDNA from a cohort of 97 patients, and analyzed the correlation between bTMB and clinical outcome. We evaluated the concordance between tTMB and bTMB using matched samples, as well as its impact on the enrichment of responders. Using data from two large randomized trials, we also explored the predictive potential of ctDNA release in NSCLC treated with PD-(L)1 blockade. A total of 108 patients with NSCLC were treated with anti-PD-(L)1 monotherapy agents at Sun Yat-sen University Cancer Center between December 2015 and August 2017, data cutoff in January 2019. According to our eligibility criteria, which were the same as previously specified,15 a total of 97 NSCLC patients with evaluable radiological results, sufficient clinical information and baseline blood samples were analyzed (Figure S1). The median follow-up time was 637 days. DCB was defined as the percentage of patients who responded or had stable disease (SD) lasted >6 months; nondurable clinical benefit was defined as the percentage of patients who experienced PD or less than 6 months of SD. Table S1 summarized the baseline clinical characteristics of the cohort. Plasma from 97 patients, as well as matched tissue samples from 66 patients, were profiled using targeted NGS with a 422-cancer-relevant gene panel (GeneseeqPrime)15 in the CLIA- and CAP-accredited Geneseeq laboratory (Nanjing, China). The mean coverage depth was 143× for controls, 1341× for tissues, and 4185× for cfDNA samples. TMB estimation was performed using clinically validated procedures as previously described.15 Analysis of the entire cohort revealed inadequate performance of bTMB in predicting patient outcome. While increasing cut-points of bTMB showed a clear monotonic relationship with progression-free survival (PFS) outcome, significant PFS difference was found between bTMB-high and -low patients only at cut-points of 13 and above (Figure S2). In this regard, bTMB assessment identified less than 20% of patients who may derive PFS benefit, showing no enrichment of responders compared with the unselected population. We have previously established the predictive value of tissue-based TMB in our cohort15 and reasoned that the failure of bTMB to predict PFS benefit must owe to the technical aspect(s) of ctDNA detection in liquid biopsy. Thus, we evaluated the influence of cfDNA concentration and ctDNA maximum somatic allele frequency (MSAF) on bTMB assessment (Figure S3). cfDNA concentration displayed a weak positive correlation with ctDNA MSAF (Spearman ρ = 0.28, P = .007) and no significant correlation with bTMB (Spearman ρ = 0.11). On the other hand, a strong correlation between ctDNA MSAF and bTMB was observed (Spearman ρ = 0.76, P < .001). Consistent with previous studies,17 we further showed that a low ctDNA MSAF negatively impacts tissue-plasma TMB concordance (Figure S4A-C). At ctDNA MSAF cut-points of 2% and above, the correlation between bTMB and tTMB became sufficiently high (Spearman ρ > 0.7), and thus samples with ctDNA MSAF <2% were excluded (Figure S1). Increasing cut-points of bTMB again demonstrated a clear monotonic relationship with improved PFS outcome (Figure 1A). At bTMB cut-points of 11 and above, bTMB-high patients experienced significant PFS benefit compared with bTMB-low patients (Figure 1A). Unlike the MSAF-unadjusted cohort, the prevalence of bTMB-high (≥11) was 32% in patients with MSAF ≥2%. High bTMB was associated with greater DCB (34.8 vs 22.5%, P = .39; Figure S2B) and significantly prolonged PFS (mPFS, 110 vs 60 days, hazard ratio [HR] = 0.54 [95%CI, 0.31–0.92]; Figure 1B). Despite substantial tumor heterogeneity in NSCLC, bTMB demonstrated a strong correlation with tTMB (Spearman ρ = 0.71; Figure 2A). To rule out the possibilities of sampling biases associated with a single tumor biopsy or net output of ctDNA that does not truly represent the mutational load of the dominant tumor clones, we focused on paired samples that were deemed TMB-high by both tissue and blood assessments. Interestingly, such patients derived a greatly improved DCB benefit (42.9 vs 22.2%, P = 0.17; Figure 2B and Figure S3A) and PFS outcome compared with patients with low TMB as assessed using either sample type (mPFS, 156 vs 59 days, HR = 0.47 [95%CI, 0.24–0.91]; Figure 2C and Figure S3B). As plasma testing may be skewed by the net output of ctDNA from diverse subpopulations of cancer cells, it is not surprising that while tTMB or bTMB assessment alone is able to identify responders to immunotherapy, concordant bTMB and tTMB status has a greatly refined predictive potential. Although a strong correlation between tTMB and bTMB was achieved by excluding patients with low ctDNA release, whether such patients may derive benefit from PD-(L)1 blockade is unknown. Indeed, ctDNA release reflects tumor anatomic and metabolic burden,22 and may correlate with patient outcome. Thus, to further enrich for potential responders, we analyzed patients according to their MSAF status. As expected, of the 25 patients with low MSAF, eight (32.0%) patients experienced DCB, with an mPFS of 129 days, which was longer than those with high MSAF (Figure S4A). Notably, all of the three “low-releasers” with discordant bTMB-tTMB had low bTMB and high tTMB and experienced DCB and long PFS of 300 days and over. Thus, insufficient ctDNA release not only masked the predictive value of bTMB, but also reflected the impact of tumor metabolic load on patient outcome. To account for the influence of MSAF on patient outcome and bTMB, we performed combined analysis of MSAF and bTMB on the entire study cohort. Remarkably, our results revealed that patients with low ctDNA release experienced similar PFS benefit as those with high bTMB from PD-(L)1 blockade (Figure 3A). Importantly, this finding was externally validated using data from two large randomized trials, POPLAR and OAK (Figure 3B and Figure S4B and C). As a consequence, our analysis led to an enrichment of potential responders from 24% to at least 50% following the integration of MSAF and bTMB into the process of patient selection for immunotherapy (Figure 3C). There are two potential mechanisms by which low ctDNA release influences outcome prediction by bTMB. Low ctDNA MSAF, and resulting “low bTMB,” oftentimes does not truly reflect the tumor's mutational status. Indeed, we find that over 18% of “low releasers” have low bTMB but high tTMB. On the other hand, ctDNA release is associated with overall tumor load and metabolic burden, and in many disease settings, correlates with patient outcome and response to therapies. Consistent with this notion, we find that patients with low ctDNA MSAF obtained PFS benefit from anti-PD-(L)1 therapies. Thus, rather than excluding the “low releasers” on the basis of inaccurate representation of bTMB, incorporation of MSAF status enriches for a large subset of potential responders. Given the association between ctDNA levels and prognosis in a number of cancer types,23, 24 it is conceivable that ctDNA MSAF might also be a prognostic biomarker. However, further investigations are necessary as our study design precluded the evaluation of the prognostic value of ctDNA MSAF or bTMB. In conclusion, our study validated the clinical utility of panel-estimated bTMB as a biomarker to identify NSCLC patients who may respond to immunotherapy. We also provided the first clinical evidence showing that matched tissue and plasma testing should be recommended when selecting patients for immunotherapy, as bTMB-tTMB discordance negatively impacts prediction of clinical outcome. On the other hand, we identified ctDNA MSAF as a novel biomarker for predicting immunotherapy outcome. Importantly, low ctDNA release is associated with significant PFS benefit and integrated analysis of MSAF, and bTMB allows for a greatly enhanced enrichment of potential responders (Figure 3C). Our results have important clinical relevance and significance in the detection of blood-based ctDNA as a source of molecular biomarkers for cancer immunotherapy. We would like to thank the patients and family members who gave consent on presenting the data in this study. L. Zhang and work in his laboratory was supported by the National Key R&D Program of China (2016YFC0905500 and 2016YFC0905503) as well as the Science and Technology Program of Guangdong (2017B020227001). W. Fang (81772476), S. Hong (81602005), and L. Zhang (81872499) were supported by Chinese National Natural Science Foundation project. S. Hong was also supported by Outstanding Young Talents Program of Sun Yat-sen University Cancer Center (16zxyc04) and Central Basic Scientific Research Fund for Colleges-Young Teacher Training Program of Sun Yat-sen University (17ykpy81). The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported. National Key R&D Program of China (2016YFC0905500, 2016YFC0905503); Science and Technology Program of Guangdong (2017B020227001); Chinese National Natural Science Foundation (81772476, 81602005, and 81872499); Outstanding Young Talents Program of Sun Yat-sen University Cancer Center (16zxyc04); Central Basic Scientific Research Fund for Colleges-Young Teacher Training Program of Sun Yat-sen University (17ykpy81). The study was conducted in accordance with declaration of Helsinki, and was approved by the Ethical Review Board of Sun Yat-sen University Cancer Center. Informed written consent was obtained from each subject or each subject's guardian. Study concept and design: Zhang and Shao. Analysis and interpretation of data: Fang, Ma, Yin, Zhou, Wang, Bao, Wang, Wu, Hong, Yang, Huang, and Zhao. All authors were involved in the drafting, review, and approval of the report and the decision to submit for publication. The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Abstract:Dear editor, The scarcity of routine metastatic biopsies or resection limits the finding of biomarkers of diagnosis and prognosis in patients with brain metastases. Derived from necrosis, apoptosis, and secretion of tumor cells, circulating tumor DNA (ctDNA) is widely distributed in various body fluids, including peripheral blood and cerebrospinal fluid (CSF), as an alternative biomarker for tumor-associated analysis [1]. Fortunately, genomic alterations of blood ctDNA and CSF ctDNA have been proven as prognostic markers in non-small cell lung cancer (NSCLC) patients with brain metastasis [2, 3]. T cell-mediated immunity is critical in suppressing oncogenesis and metastasis of NSCLC. Targeted sequencing in the highly variable complementarity-determining region 3 (CDR3) region of the beta chain of the T cell repertoire (TCR) provides a robust method to quantify T cell diversity [4]. Casarrubios et al. [5] reported that the evenness of pretreatment TCR was related to the clinical response of NSCLC patients receiving neoadjuvant chemotherapy plus immunotherapy. Radiotherapy may stimulate immune responses against malignancies. Locally, irradiation causes antigen exposure by directly destroying cancer cells, which activates both the local and systemic immune systems. Irradiation can also cause DNA damage, and the ensuing mutations in cells with DNA mismatch repair deficiencies might increase the load of neoantigens, triggering an immunological response [6]. The PACIFIC trial demonstrated that combining radiotherapy and immunotherapy was effective in prolonging the survival of stage III NSCLC patients [7]. The TCR, which is closely associated with immune system modifications, also alters as a result of irradiation. Therefore, we investigated the dynamic changes of ctDNA and TCR during radiotherapy and the associations of ctDNA and TCR profiling in blood and CSF with radiotherapeutic responses and prognosis of NSCLC brain metastases. To address these questions, 30 NSCLC patients with brain metastases, diagnosed between February 2017 and December 2018, receiving brain radiotherapy were enrolled in the study (Supplementary Table S1). Peripheral blood and CSF samples were collected at baseline, 24 h (T0), and 28 days (T28) after completion of radiotherapy and underwent deep sequencing of ctDNA and TCR CDR3 regions (Supplementary Table S2). The 6-month response rates of brain metastases and systemic lesions were evaluated based on Response Evaluation Criteria in Solid Tumors version 1.1 for further study. Details of methods are provided in the Supplementary file. Excluding samples with deficient cell free DNA (cfDNA) extraction, ctDNA was tested in 83 blood and 75 CSF samples (Supplementary Table S3). Collectively, 107 and 153 mutations, including single nucleotide variants and small insertions and deletions, were detected in 18 (69.2%) of 26 blood samples and 22 (81.5%) of 27 CSF samples at baseline, respectively. For 25 patients with paired blood-CSF samples with sufficient cfDNA extraction, 55 (27.4%) mutations were shared between blood and CSF samples in 9 patients, whereas 52 (25.9%) were detected only in blood samples and 94 (46.8%) only in CSF samples. The top ten mutation genes with the average variant allele frequency in blood and CSF were identical; however, the representative genes of various samples were distinct (Supplementary Figures S4-S5). TCR sequencing was performed in 87 blood and 77 CSF samples (Supplementary Table S4). The results from partial least squares discriminant analysis showed that CSF TCR could be distinguished from the blood TCR via the dimensionality reduction of V and J gene usage (Figure 1A). The number of TCR clones was significantly greater in the blood than in the CSF at baseline, and few clones were shared (Supplementary Figure S6). These results suggested that the CSF and peripheral blood were independent compartments showing disparate genomic evolution and immune signatures. Therapeutic efficacy associated with TCR dynamic and ctDNA burden in peripheral blood and CSF throughout radiotherapy for brain metastasis in non-small cell lung cancer patients. (A) PLS-DA clusters reveal distinct V and J gene recombination of blood (circle) and CSF (triangle) TCR. All samples with available TCR results were included. (B) Broken line graphs showing the dynamic changes of Shannon entropy, clone count, and MCF in blood or CSF sample from each patient. Statistical analysis was performed using paired-sample t-tests (two-sided). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, no statistical significance. (C) The left three panels indicate the percentage changes of blood TCR parameters in patients with different pulmonary responses, and the right panel indicates the differential prediction capability of ctDNA AF in baseline, T0, and T28 blood samples using ROC analysis. (D-F) Kaplan-Meier curves are shown for OS (D), PFS (E), and iPFS (F). The blood or CSF ctDNA and TCR parameters were tested. ctDNA status was determined at T28, and recovered diversity indicates non-inferiority Shannon at T28 compared with baseline. The greater MCF increase at T0 or T28 benchmarked baseline is identified as the basis for grouping. Abbreviations: T0, within 24 h after completion of radiotherapy; T28, 28 days after completion of radiotherapy; AF, allele frequency; AUC, area under curve; CSF, cerebrospinal fluid; ctDNA, circulating tumor DNA; HR, hazard ratio; iPFS, intracranial PFS; MCF, maximum clone frequency; OS, overall survival; PFS, progression-free survival; PLS−DA, partial least squares discriminant analysis; ROC, receiver operating characteristic; RT, radiotherapy; SRT, stereotactic radiotherapy; TCR, T cell repertoire; WBRT, whole-brain radiotherapy. Maximum allele frequency (MAF) and tumor mutational burden were the main parameters of ctDNA detection; shannon entropy, clone count, and the maximum clone frequency (MCF) were utilized to assess TCR diversity. The comparison of ctDNA and TCR key parameters at baseline revealed significant differences in MAF, Shannon entropy and clone number between blood and CSF (Supplementary Figure S7), supporting the previously stated view. Based on a pair-wise analysis, the Shannon entropy of both blood and CSF samples was decreased at T0 compared with baseline. The clone count in blood samples was significantly decreased at T0 compared with baseline, and then recovered at T28. However, the clone count in CSF samples showed no significant differences at the three time points. The MCF in both blood and CSF samples was increased at T0 compared with baseline, although the expansion pattern might be disparate. The MCF in blood samples at T28 was still greater than that at baseline, but there was no significant difference in MCF between baseline and T28 in CSF samples (Figure 1B). The intracranial and systemic object response rates were 83.3% and 76.6% in our cohort, respectively. For patients with partial response, the dynamic change of blood Shannon entropy from baseline to T0 tended to be higher (P = 0.097 at T0, P = 0.265 at T28), and the clone count in each patient experienced a significant and persistent increase (P = 0.007 at T0, P = 0.004 at T28) compared with those with progressive disease or stable disease, indicating that patients with partial response seemed to maintain an activated immune repertoire to resist the radiotherapy-induced stress response. Receiver operating characteristic analysis further evaluated the predictive effect of allele frequency of blood ctDNA in distinguishing patients who would benefit from radiotherapy, and the area under curve reached 0.74 at T28 (Figure 1C). With a median follow-up of 24 months, the overall survival (OS) was significantly increased in patients without ctDNA residual or with non-inferior Shannon entropy (defined as recovered diversity) in blood at T28. When we simultaneously looked at two factors, and the combination of ctDNA and TCR diversity exhibited an even better predictive performance for OS than individual ctDNA or TCR diversity [median: unreached vs. 6.1 months; hazard ratio (HR) = 10.53, P < 0.001] (Figure 1D). Similar results were obtained for progression-free survival (PFS) (Figure 1E). Intracranial PFS (iPFS) was also regarded as an independent endpoint of this study. Patients with CSF MCF increased by ≥ 50% had longer iPFS than those with CSF MCF increased by <50% (median: unreached vs. 6.0 month; HR = 8.320, P = 0.011) (Figure 1F), indicating that the expansion of T cell clones in the CSF might serve as a potential prognostic marker for radiotherapy in the brain metastasis treatment. In addition, the combination of ctDNA and CSF MCF did not enhance the predictive power (Supplementary Figure S8). The combination of ctDNA residual and TCR diversity change in blood at T28 was still powerful in predicting OS (HR = 0.024, P < 0.001) and PFS (HR = 0.083, P < 0.001) independent of clinical factors in multivariate Cox model analysis. Especially, the MCF with ≥ 50% increase in CSF was also an independent protective factor for iPFS (HR = 0.028, P = 0.008) (Supplementary Table S5). Note that systemic treatment may bias research results; this effect needs to be validated in a larger sample size. This study characterized the longitudinal profile of genomic and immune statuses in both CSF and peripheral blood samples from NSCLC patients with brain metastases treated with cranial radiotherapy. TCR in blood boosted the prognostic capacity of ctDNA in NSCLC patients following brain radiotherapy, whereas TCR in CSF could predict the iPFS independently. Ling Peng: Conceptualization, Methodology. Yawen Bin: Investigation, Data curation. Peng Ding and Lingjuan Chen: Formal analysis, Writing-Original draft preparation. Hao Zeng, Zelong Xu, Liyan Ji and Xuan Gao: Formal analysis, Visualization and Sequencing. Ye Wang and Sheng Zhang: Radiotherapy technical support. Pian Liu and Zhongxing Liao: Clinical research support, Formal analysis. Xuefeng Xia and Ruiguang Zhang: Project administration, Validation. Fan Tong and Xiaorong Dong: Writing- Reviewing and Editing, Supervision and Funding acquisition. The authors would like to thank the patients, their families and caregivers, trial nurses, data managers, and all study investigators for their contributions to the study. The authors declare no conflicts of interest The study was conducted according to the Declaration of Helsinki. All patients provided written informed consent before study procedures began. The protocol was approved by the Institutional Review Board of Union Hospital affiliated to Tongji Medical College, Huazhong University of Science and Technology (No. 0116) and registered on the ClinicalTrials.gov under the number NCT05737589. This work was supported by the National Natural Science Foundation of China (81573090, 81773233). Written informed consent for publication was obtained from all participants. All data generated or analyzed during this study are included in this published article and its supplementary information files or from the corresponding author upon reasonable request. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Combinatorial Assessment of Ctdna Release and Mutational Burden Predicts Anti‐pd(l)1 Therapy Outcome in Nonsmall‐cell Lung Cancer

Serial Monitoring of Circulating Tumour DNA on Clinical Outcome in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.

Abstract 707: Combinatorial Assessment of Ctdna Release and Mutational Burden Predicts Clinical Outcome from Anti-Pd-(l)1 Therapies in Non-Small-cell Lung Cancer

Blood Tumor Mutation Burden Can Predict the Clinical Response to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients

Maximum somatic allele frequency-adjusted blood-based tumor mutational burden balances the effect of intratumor heterogeneity on response to immune checkpoint Inhibitors in non-small cell lung cancer patients.

In Reply: A Modified Algorithm Adjusting Both High and Minor Allele-Frequency to Redefine Blood-Based Tumor Mutational Burden for Optimal Prediction of Clinical Benefits from Programmed Cell Death-Protein 1 Immunotherapy

Abstract 4056: Correlation Analysis Between PD-L1 Expression, TMB and Clinical Characteristics in Chinese Non-Small Cell Lung Cancer

Abstract PO5-14-05: Circulating tumor DNA fraction correlates with residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer patients

P2.01-116 the Potential of Assessing Blood Tumor Mutation Burden (btmb) Using a Large Panel

Blood-based tumor mutational burden from circulating tumor DNA (ctDNA) across advanced solid malignancies using a commercially available liquid biopsy assay.

Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure.

Integrated Circulating Tumor DNA and T Cell Repertoire Predict Radiotherapeutic Response and Outcome in Non‐small Cell Lung Cancer Patients with Brain Metastasis

Dynamic bTMB combined with residual ctDNA improves survival prediction in locally advanced NSCLC patients with chemoradiotherapy and consolidation immunotherapy

Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB

Abstract 6443: Enhanced detection of ctDNA molecular response for immunotherapy treated non-small cell lung cancer through analyses of cell-free and matched white blood cell DNA

Theoretical Model and Clinical Validation of Blood Tumor Mutation Burden (btmb) Detection for Cancer Immunotherapy.

Dynamic Alterations of Ctdna Associate with the Therapeutic Outcome in the Advanced Non-Small Cell Lung Cancer Patients Who Received Sintilimab Plus Anlotinib Regime As 1st Line Therapy.

Blood-based Tumor Mutational Burden As a Predictor of Clinical Benefit in Non-Small-cell Lung Cancer Patients Treated with Atezolizumab

Abstract 6557: Longitudinal cell-free tumor load dynamics represent an early endpoint for immunotherapy response in non-small cell lung cancer

Maximum Somatic Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden Predicts the Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

Prognostic and Predictive Impact of Molecular Tumor Burden Index in Non‐small Cell Lung Cancer Patients